Close Menu

NEW YORK (GenomeWeb) – Molecular diagnostics firm Admera Health announced today that it has received approval from the New York State Clinical Laboratory Evaluation Program for its 50-gene PGxOne Plus pharmacogenomics test. 

PGxOne Plus uses next-generation sequencing technology to interrogate genes with the aim of predicting how patients will respond to drug therapy in cardiology, psychiatry, pain management, and oncology, among other areas. Reports sent to clinicians include information on whether specific drugs should be avoided, alternative treatments, and dosage adjustments.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.